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ABSTRACT

THE ROLE OF WNT SIGNALING IN DEVELOPMENT OF THE
OPHTHALMIC TRIGEMINAL PLACODE

Rhonda N. T. Lassiter
Department of Physiology and Developmental Biology
Doctor of Philosophy

Cranial placodes are ectodermal regions that contribute extensively to the
vertebrate peripheral nervous system. The development of the ophthalmic trigeminal
(opV) placode, which gives rise only to sensory neurons of the ophthalmic lobe of the
trigeminal ganglion, is a well-studied model of sensory neuron development. While key
differentiation processes have been characterized at the tissue and cellular levels, the
molecules governing opV placode development have not been well described. This study
identifies the canonical Wnt signaling pathway as a regulator of opV trigeminal placode
development. Introducing dominant-negative TCF and dominant-active β-catenin
expression constructs by in ovo electroporation, we have manipulated the canonical Wnt
pathway within the opV placode domain and surrounding ectoderm of chick embryos.
Inhibition of canonical Wnt signaling results in the failure of targeted cells to express or
maintain Pax3 protein, the earliest known specific molecular marker of opV placode

cells. Misexpression of dominant-active β-catenin as an activator of canonical Wnt
signaling, however, is not sufficient to promote the opV placode cell fate. We conclude
that canonical Wnt signaling is necessary for normal opV placode development, and
propose that other molecular cues are required in addition to Wnt signaling to promote
cells to an opV placode fate. Strategies for manipulating the Wnt pathway at the level of
ligand and receptor are also reviewed. Because it is clear that Wnt signaling is not acting
alone in early development of the opV placode, we have also begun to investigate
additional signaling pathways, such as FGFs, that may be involved in these
developmental processes.
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Chapter 1
Strategies for Inhibition of Wnt Signaling
in the Ophthalmic Trigeminal Placode
Introduction
Sensory neurons originate from two embryonic cell populations, the neural crest
and the cranial placodes. Cranial placodes are focal regions of epithelium that form in
distinct locations in vertebrate head ectoderm. The trigeminal and epibranchial placodes
give rise exclusively to sensory neurons, whereas other cranial placodes form a variety of
cell types such as neuroendocrine and glial cells. Because sensory neurons are the sole
derivatives of the trigeminal placode it is an ideal experimental system to study their
development. The trigeminal placode consists of two separate branches, the ophthalmic
and the maxillo-mandibular. In a previous study Stark et al., 1997 identified the paireddomain homeobox transcription factor Pax3 as an early marker of the avian ophthalmic
trigeminal (opV) placode (Fig. 1A). This placode gives rise to the sensory neurons in the
ophthalmic lobe of the trigeminal ganglion (opV). Here we have utilized the opV placode
to investigate the inductive events necessary that initiate the transformation from preplacodal ectoderm to a specified sensory neuron cell fate.
Previously, through use of the Pax3 molecular marker, it was found that the
inducing signal for the opV placode originates from the dorsal neural tube in the region
of the midbrain/rostral hindbrain (Stark et. al., 1997). By inserting various barriers
between the neural tube and ectoderm in the region of the opV placode, it was shown that
a diffusible signal(s) from the neural tube induces Pax3 expression in the placode.
Additional grafting experiments showed that the inducing signal is expressed throughout
the majority of the neural tube with a slight decrease in inducing activity at the level of

1

A

B

C

D

Pax3

Figure 1. Gene Expression in the Ophthalmic Placode
Expression pattern of Pax3, Wnt-1, Fz-2, and Fz-7 in the developing chick ophthalmic
placode as revealed by whole-mount in situ hybridization. (A) A HH stage 12 chick
embryo with Pax3 expression in ophthalmic placode cells. Pax3 expression is also
evident in the neural tube and somites. (B) A HH stage 10 embryo showing high level of
Wnt-1 expression in the midbrain with a characteristic gap of expression in the rostral
hindbrain with lower levels of expression continuing throughout the rest of the caudal
neural tube. (C) In a HH stage 9 embryo Fz-2 can be detected throughout the cranial
ectoderm and in the somites. (D) In a HH stage 9 embryo Fz-7 is seen in the cranial
ectoderm beginning to be restricted to the presumptive trigeminal ectoderm.
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rhombomeres 2 and 3 (Baker et al., 1999). It was also shown that the entire head
ectoderm rostral to the first somite is competent to receive the inducing signal from the
neural tube, with a loss of competence in the otic region beginning at the 4 somite stage.
Following these experiments, we aimed to identify the candidate molecules responsible
for the signaling interactions leading to the induction of the ophthalmic trigeminal
placode.
The Wnt/Frizzled signaling pathway was among the primary candidates likely to
play a role in opV placode induction. Spatiotemporal gene expression of both Wnt-1 and
Wnt-3a, in the dorsal neural tube, correlate with Pax3 inducing activity in the placode
(Hollyday et al., 1995; Fig. 1B). In 2000, Stark et al., characterized the Wnt seven
α-helical transmembrane receptors, Frizzleds (Fz), in the chick embryo. Fz-7 is expressed
early in competent cranial ectoderm and becomes restricted to the opV placode region as
development proceeds (Fig. 1D). Fz-2 was also shown to be broadly expressed in the
cranial ectoderm (Fig.1C). Together, this expression data supported a potential role for
Wnt/Frizzled signaling in opV placode induction.
Wnt/Frizzled signaling is involved throughout development in both vertebrates
and invertebrates. Wnt embryonic functions include establishing cell polarity, regulating
cell proliferation, and determining cell fate specification and differentiation. In
Drosophila, Wingless (the Wnt homologue) is important for normal neurogenesis in the
CNS (reviewed in Bhat, 1998). In vertebrates, Wnt-1 and Wnt-3a are involved in
development of midbrain/hindbrain boundary (MHB) formation. Studies performed by
McMahon and Bradley (1990) show that in the absence of Wnt-1, a deletion of the
midbrain as well as a substantial portion of the rostral hindbrain results. Wnt-3a knock
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out mice result in malformations of the forebrain as well as an abnormal spinal cord
starting from the forelimb bud continuing caudally with a loss of caudal somites
(Augustine et al., 1993; Takada et al., 1994). Interestingly, in Wnt-1 null and Wnt1/Wnt-3a double knockout mice the ophthalmic branch of the trigeminal nerve is
significantly reduced, whereas Wnt-3a null mice have normal opV branching (Ikeya et
al., 1997).
The model proposed in this study suggests that a Wnt signal secreted from the
dorsal neural tube binds to Fz receptors in competent ectoderm, thereby inducing Pax3
and initiating induction of the opV placode (Fig. 2). There are numerous methods of
manipulating a signal transduction pathway in vivo. These approaches include blocking
the action of the ligand in the extracellular matrix, or inhibiting expression of the
receptor. It is also possible to activate a pathway in excess or at a different time in
development by misexpressing functional ligand and/or receptor. Manipulating a pathway
at the intracellular level by introducing dominant-negative or dominant-active
downstream molecules and/or transcription factors can also alter gene expression.
Multiple approaches were utilized to investigate the role of Wnt signaling in opV placode
development. Initial experiments focused on blocking Wnt/Frizzled signaling at the level
of ligand-receptor function. A function blocking Wnt antibody was used to bind the Wnt
ligand expressed from the neural tube. Following this approach, specific inhibition of Fz7 was performed utilizing RNAi and morpholino technology. Effectively blocking Wnt
signaling in vivo at the ligand-receptor level is difficult and these preliminary studies did
not result in loss or reduction of Pax3. Subsequent research (see Chapter 2) focuses on
manipulation of the Wnt pathway through intracellular components (Fig. 3).
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Figure 2. Model of opV Placode Induction
Diagram depicting the hypothesized model of placode induction. The purple regions
highlighted in the neural tube correspond to regions where Pax3 inducing activity can be
found. This correlates with the spatiotemporal expression of both Wnt-1 and Wnt-3a.
Blue regions depict cranial ectoderm competent to receive the signal from the dorsal
neural tube that will induce expression of Pax3. Both Fz-2 and Fz-7 are expressed in this
competent ectoderm at the time correlating with inductive events. The Wnt/Fz expression
pattern suggests a likely role for Wnt signaling in early opV placode induction with Wnt
ligand being secreted from the NT through the mesenchyme where it is bound by the Fz
receptors in the placodal ectoderm thereby inducing Pax3 in the placode.
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Figure 3. The Canonical Wnt Signaling Pathway
Simplified overview of the canonical Wnt signalling pathway (Pinto and Clevers, 2005
(adapted from He et al., 2003)) (A) In the absence of Wnt ligand, β-catenin is sequestered
in a multiprotein degradation complex containing the scaffold protein Axin, the tumor
suppressor gene product APC, as well as the kinases CKI and GSK3β, among others.
Upon sequential phosphorylation, β-catenin is ubiquitinated by the β-TrCP–E3-ligase
complex and subsequently degraded by the proteasome machinery. (B) Wnt ligand
associates with Fz and LRP5/6 co-receptors. This in turn leads to degradation and/or
dissociation of the multiprotein complex through the action of Dsh. β-catenin is then
released from the multiprotein complex, accumulates in the cytoplasm in a nonphosphorylated form, and subsequently translocates into the nucleus whereby association
with TCF/LEF transcription factors promotes transcription of Wnt target genes.
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Materials and Methods
Wingless Antibody Cell Injection
Cell lines were cultured in DMEM, FBS, and chick serum. Cells were pelleted by
centrifugation and labeled with DiI. The cells were then injected between the neural tube
and head ectoderm using a picospritzer microinjector and pulled glass pipet. The embryos
were incubated for 24 hours and then collected and prepared for in situ hybridization.
Embryos were analyzed for the presence or absence of Pax3 mRNA in the opV placode.
Epifluorescent microscopy was used to visualize DiI labeled injected cells.
Wg-antibody cells (4D4): The 4D4 cell line (Developmental Studies Hybridoma
Bank) secretes an antibody specific to the Drosophila wingless, Wg, protein (aa 3-468).
Wg is homologous to the Wnt-1 gene in the chick embryo. The Wg antibody has been
shown to inhibit the function of exogenous Wg protein in chick explant cultures (GarcíaCastro et al., 2002). The 4D4 cells were collected to use in cell-injection experiments
described above to knockdown the function of Wnt proteins in the head ectoderm.
Neurofilament cells (3A10): The 3A10 cell-line (Developmental Studies
Hybridoma Bank) express a neurofilament associated antibody originating from ventral
spinal cord and assorted nervous tissue in the chick. The 3A10 cells were collected for
use as a control in cell injection experiments.
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Short Interfering RNA (siRNA)
The Ambion siRNA cocktail kit was used to knockdown the function of the
Frizzled-7 (Fz-7) transmembrane receptor. The kit generates a cocktail of siRNA from a
template of the target gene 150-500 base pairs in length. The E. coli RNAse III then
digests the template dsRNA into siRNA which is then introduced into cells. The siRNA
cocktail was designed from the 3΄ region of the Fz-7 gene (bp 2590-2801). The Fz-7.3΄
siRNA was introduced by in ovo electroporation into 2-6 ss chick embryos. A GAPDH
siRNA cocktail provided by the manufacturer was used as a control. The siRNA was
labeled with Cy3 using an Ambion labeling kit in order to visualize the targeting. The
embryos were incubated for 24hrs, collected, prepared for in situ hybridization and
immunohistochemistry, and analyzed for Pax3 expression.

Antisense Morpholino Oligonucletides
Fluorescein-tagged morpholinos were obtained from Gene Tools, LLC. An
antisense Gallus Gallus Fz-7 morpholino (GenBank Accession number #AF224317) was
custom designed by Gene Tools to bind to the 5' UTR sequence including the initiation
methionine to prevent translation initiation through steric inhibition
(5'-CGCGGCGTTCCTCCTCGCCC-3'). The morpholino antisense oligo is constructed
from the nucleotide sequence linked to a morpholine ring which replaces the ribose sugar.
A standard control morpholino (5'-CCTCTTACCTCAGTTACAATTTATA-3') was used
in control embryos. Fz-7 and standard control morpholinos were resuspended in nanopure
water [10 µg/µl] and stored at -80ºC in 10 µl aliquots until use. Morpholinos were diluted
to a 5ug/ul working solution in 15% sucrose/fast green solution in preparation for in ovo
electroporation.
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In ovo Electroporation
The Fz-7 morpholino or siRNA was injected into target regions of head ectoderm
using a picospritzer microinjector and pulled glass pipets. Fast green was used to
visualize injected constructs. Electrodes were then placed on either side of the head, with
the driving electrode beside the presumptive placode, and a current was applied using a
BTX pulse electroporator (10V, 10msec, 5 pulses). The current creates transient pores in
the cell membranes allowing for the inhibitory constructs to enter. Embryos were then
sealed and incubated for appropriate time periods.

Immunohistochemistry
Prior to antibody staining, embryos were embedded in gelatin and cryosectioned
to generate 12 µm sections of the area of interest. Sections were mounted on Superfrost®
Plus glass slides and the gelatin removed by treating the slides in phosphate-buffered
saline (PBS) at 37°C for 15-20 minutes. Embryo sections were then incubated overnight
at 4°C in Pax3 primary antibody (Baker et al., 1999) diluted 1:200 in antibody buffer
(PBS, 0.1% bovine serum albumen, 0.1% triton-X100), followed by incubation for 1 hour
in Alexa546- or Alexa488-conjugated goat anti-mouse IgG2a (Molecular Probes) diluted
1:500 in antibody buffer. Three 5-10 minute washes in PBS followed each incubation.
Sections were analyzed using epifluorescent microscopy.

Whole-mount in situ hybridization
A chicken Pax3 (Matsunaga, et al., 2001) digoxigenin-labeled RNA probe was
synthesized and used for whole-mount in situ hybridization on chick embryos as

13

described by Henrique et al. (1995). Briefly, formaldehyde-fixed embryos of appropriate
developmental stages were buffered and exposed to digoxigenin (DIG)-labeled anti-sense
RNA probes, which recognized the Pax3 mRNA transcripts. After removal of the nonspecifically adhering probe, the embryos were incubated with an alkaline phosphatase
(AP)-labeled anti-DIG antibody, followed by a chromogenic substrate for AP.

Results
Inhibition of Wnt signaling by anti-wg cell injection does not lead to a loss in placodal
Pax3 expression
The Pax3 inducing signal has been shown to originate from the neural tube where
multiple Wnt genes are expressed. To test whether Wnt signaling is responsible for Pax3
induction, we inhibited the Wnt ligand and looked for downregulation of Pax3 mRNA.
Wnt signaling was blocked using the function blocking antibody to the Drosophila
homologue Wg (Garcia-Castro et al., 2002). Cells from the 4D4 cell-line, which secrete
Wg-antibody, were pelleted and labeled with DiI. The labeled cells were injected into the
mesenchyme between the neural tube and competent head ectoderm in 2-6ss chick
embryos. Embryos were allowed to develop for 24 hours, collected and prepared for
whole-mount in situ hybridization, followed by cryosectioning. Neurofilament cells
(3A10) were used as a control. Experimental embryos (n=35) did not show a difference
or any apparent reduction in Pax3 mRNA expression, in whole-mount or in section, in the
opV placode when compared to control embryos (n=20, Fig. 4).
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Figure 4. Anti-Wg Antibody Wnt Inhibition
Blocking Wnt signaling with function blocking antibody does not reduce Pax3 mRNA
expression in the placode. Section of embryo in opV placodal region. (A) 4D4 anti-Wg
antibody secreting cells labeled with DiI injected into the mesenchyme between the NT
and ectoderm to inhibit endogenous Wnt protein. Labeled cells shown in red. (B)
Corresponding section of embryo after whole-mount in situ hybridization for Pax3. Pax3
mRNA can be seen in placodal ectoderm in purple with no obvious reduction on the
experimental side when compared to contralateral control side or in embryos injected
with control cells (data not shown).
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Inhibition of Wnt signaling by blocking Frizzled-7 receptor function via siRNA or
Morpholino does not result in a loss of Pax3 in the opV placode
Chick Frizzled-7 mRNA is expressed beginning at the 3ss in cranial ectoderm, it
then becomes restricted to the presumptive trigeminal placode and persists through the
25ss. Previous experiments using a secreted-Frizzled-7 receptor had shown a variable
loss of Pax3 in the opV placode. Because loss of Pax3 was inconsistent, we decided to
use two methods to specifically inhibit the Fz-7 receptor.
Initially, Fz-7 siRNA was prepared and used to inhibit expression in opV placodal
ectoderm. The Fz-7 siRNA was introduced using electroporation into head ectoderm of
2-6ss chick embryos. Embryos were allowed to develop for 24hrs., a stage correlating to
peak Pax3 expression. Embryos were then collected and prepared for either whole-mount
in situ hybridization or immunohistochemistry. Whole-mount embryos analyzed by ISH
for Pax3 expression (n=17) exhibited no difference when compared to control embryos
(n=15, data not shown). A GAPDH siRNA supplied by the manufacturer (Ambion Inc.)
was used in control electroporations. Fz-7 siRNA did not result in a loss of Pax3 mRNA
expression in the placode. Embryos were then analyzed in section by
immunohistochemistry for Pax3 protein expression. The siRNA was labeled with a Cy3tag which allowed the targeted cells to be visualized by fluorescent microscopy.
Experimental embryos (n=6) containing the Fz-7 siRNA in section did not result in a
reduction of Pax3 protein when compared to control embryos (n=4, Fig. 5). This result
suggests that Fz-7 is not required for Pax3 expression.
To confirm siRNA results that Fz-7 is not necessary for Pax3 expression, we
purchased the commercially prepared inhibitor, morpholino, from Gene-tools, Inc. A
Fz-7 morpholino (Fz-7MO) was electroporated into 2-6ss embryos to inhibit translation
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of Fz-7 protein. Embryos were collected after a 24hr incubation and prepared for
immunohistochemistry. A standard control morpholino (COMO) (Gene-tools, Inc.)
commercially prepared was electroporated into control embryos. Both Fz-7MO and the
COMO had a fluorescein tag used to visualize targeted cells. Experimental and control
embryos were sectioned and immunostained for Pax3 protein in the placodal ectoderm.
Because morpholino’s can be found in both the nucleus and cytosol, sections were also
stained with the nuclear marker DAPI to distinguish individual cells. Fz-7MO did not
result in a loss of Pax3 in cells expressing the morpholino or in neighboring cells (n=10)
when compared to COMO (n=7, Fig. 6). This supports siRNA data and suggests that Fz-7
is not necessary for Pax3 expression and therefore is not required for opV placode
induction.
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Figure 5. Frizzled-7 siRNA Inhibition
Blocking Wnt signaling through inhibition of the Fz-7 receptor via siRNA does not
reduce Pax3 protein expression. Section of embryo in the opV placodal region
electroporated with siRNA at the 2-6ss, allowed to develop for 24hrs then analyzed for
Pax3 protein expression. (A) GAPDH control siRNA (red) electroporated into cranial
ectoderm on the right side of embryo with normal Pax3 expression shown in green. (B)
Fz-7 siRNA (red) does not lead to significant reduction of Pax3 (green).
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Figure 6. Frizzled-7 Morpholino Inhibition
Specific inhibition of Fz-7, the Wnt receptor, using Fz-7 morpholino does not block
induction or expression of Pax3 protein in placodal ectoderm. (A) Control morpholino,
COMO (green), electroporated into competent ectoderm at the 2-6ss collected 24hr posttransfection with high level Pax3 expression (red). (B) Fz-7MO (green) in placodal
ectoderm does not prevent Pax3 protein expression shown in red (overlapping cells
shown in yellow).
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Discussion
Inhibition of Wnt signaling utilizing secreted Wg-antibody is not sufficient to reduce
Pax3 mRNA in the opV placode
The Pax3 inducing signal for the opV placode originates from the dorsal neural
tube where both Wnt-1 and Wnt-3a are found. To inhibit Wnt signaling from the neural
tube, anti-Wg antibody was injected into head mesenchyme beneath competent ectoderm.
Blocking Wnt signaling via anti-Wg antibody resulted in no difference or reduction of
Pax3 compared to controls. There are many possibilities as to why Pax3 expression was
not affected. The first possibility is that the Wg-antibody cell injection was effective in
blocking Wnt signaling and therefore shows that Wnt is not involved in Pax3 induction.
An alternative explanation is that the antibody was not sufficient to completely block
signaling and enough Wnt ligand was available to induce Pax3 mRNA expression.
Because the Wnt ligand is a secreted factor released into the mesenchyme and is found
throughout the length of the neural tube it is difficult to block all Wnt activity. Even with
sufficient excess of Wg inhibitor it is still possible that Wnt signals are reaching the
placodal ectoderm. It is also possible that cells from surrounding competent ectoderm are
compensating for cells that did not receive ligand and migrating to form a fully functional
placode expressing Pax3. Nevertheless, there is still an expectation that sufficient
inhibition would be present to observe a minimal reduction, which was never seen. In
both whole-mount embryos and sections there did not appear to be a decrease in Pax3
expression in the placode. Finally, it is also possible that the anti-Wg antibody did not
bind the chick Wnt protein in a way that was function blocking.
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The Frizzled-7 Wnt receptor may not be required for opV placode induction
Previous experiments had shown that inhibiting the Frizzled receptors, in placodal
ectoderm, using a secreted-Fz construct led to reduction of Pax3 mRNA in section, but
the results from these experiments were inconsistent. We then decided to look
specifically at the Fz-7 receptor, whose spatiotemporal gene expression pattern makes it
the most likely candidate for a competence factor in the placodal ectoderm (Stark et al.,
2000). We hypothesized that Wnt ligand is secreted from the dorsal neural tube and
travels through the mesenchyme to the competent ectoderm, where the Fz-7 receptor
receives the signal. This in turn would initiate an intracellular cascade resulting in
expression of Pax3. However, inhibiting Fz-7 receptor function by siRNA or morpholino
did not affect Pax3 mRNA or protein expression in the opV placode.
Inhibition of Fz-7 using novel siRNA technology did not reduce Pax3 mRNA
expression as observed through whole-mount in situ hybridization nor did it affect Pax3
protein expression assayed by immunohistochemistry. At the time these experiments
were performed siRNA was a new method of inhibition without any data published in the
chick. The lack of a Fz-7 antibody specific to chick made it difficult to test whether the
siRNA was effectively blocking Fz-7 expression. Mouse frizzled antibodies were tried in
cell culture and though they did recognize the Fz receptors in chick, they were not
specific (data not shown). Both the Fz-1 and Fz-7 mouse antibodies recognized Fz-7
protein, as well as Fz-1. To confirm the siRNA data, a different method for inhibiting Fz7 was used.
Morpholino technology, though somewhat recent, was more established than
siRNA and a product that was commercially designed and prepared. But again, blocking
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Fz-7 translation by introducing the Fz-7MO into cranial ectoderm did not affect Pax3
expression. During the initial observation of these embryos in section, it appeared that the
fluorescein-tagged Fz-7MO did not co-localize with Pax3, leading to the conclusion that
targeted cells did not express Pax3 and inhibition of Fz-7 led to a cell-autonomous
inhibition of Pax3. However, a similar phenotype was observed in control embryos.
Further examination of the embryos using DAPI staining revealed that the lack of colocalization in experimental embryos was only an artifact of the experiment. The
morpholino was primarily localized in the cytosol as opposed to the nuclear expression of
Pax3, with the morpholino and Pax3 being found in the same cells. Therefore, this
suggests that Fz-7 is not required for Pax3 expression and thus not required for opV
placode induction. However, without the use of an antibody to demonstrate successful
inhibition of Fz-7, a firm conclusion on the role of Fz-7 in opV placode induction cannot
be stated.
Though Fz-7 may not be the sole receptor necessary in opV placode induction it
may still play an important role. Fz-7 is one of at least ten receptors in the frizzled, sevenpass transmembrane, receptor family. Not only does Fz-7 share significant homology
with both Fz-1 and Fz-2 but its spatiotemporal expression pattern overlaps dramatically
with Fz-2 in competent cranial ectoderm. Fz-2 is faintly expressed as early as the 3ss in
cranial ectoderm, by the 7-10ss it becomes broadly expressed and continues through the
25ss. It is possible that another Fz gene, specifically Fz-2, is performing a redundant
function and compensating for the loss of Fz-7. One possibility is that both receptors
need to be blocked in order for a phenotype to be observed. To test this hypothesis,
experiments combining Fz-2 and Fz-7 inhibitors need to be performed as well as Fz-2
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alone. Though these follow up experiments were planned, the lack of a Fz-7 or Fz-2
antibody and the availability of new reagents shifted the course of our future experiments.
Two intracellular constructs were made available to us by Dr. Jeffery, Barrow, which
would inhibit and activate canonical Wnt signaling, bypassing difficult ligand-receptor
experiments. The dominant-negative TCF and dominant-active β-catenin constructs
allowed us to consider the question as to whether canonical Wnt signaling was involved
at all in opV placode induction (Fig. 7).
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Figure 7. Misexpression Vectors
Wnt signaling Misexpression vectors (adapted from Megason and McMahon, 2002).
Both dominant-active β-catenin (DA-βcat) and dominant-negative TCF (DN-TCF) were
inserted into the pCIG vector (6.2kb). The pCIG construct contains a CMV enhancer,
β-actin promoter, and an internal ribosome entry sequence (IRES) followed by a nuclear
localized GFP for cell-autonomous recognition. The DA-βcat insert (2.5kb) contains
β-catenin with an in-frame N-terminal deletion of amino acids 29-48, removing the
GSK-3β recognition site, thereby making it resistant to targeted proteolysis. DN-TCF
(2.2kb) contains TCF with an in frame N-terminal deletion of the β-catenin binding
domain, consisting of amino acids 2-53, resulting in a constitutive transcriptional
repressor (Tetsu and McCormick).
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Abstract

Cranial placodes are ectodermal regions that contribute extensively to the vertebrate
peripheral nervous system. The development of the ophthalmic trigeminal (opV)
placode, which gives rise only to sensory neurons of the ophthalmic lobe of the
trigeminal ganglion, is a well-studied model of sensory neuron development. While key
differentiation processes have been characterized at the tissue and cellular levels, the
molecules governing opV placode development have not been well described. We have
identified the canonical Wnt signaling pathway as a regulator of opV trigeminal placode
development. Introducing dominant-negative TCF and dominant-active β-catenin
expression constructs by in ovo electroporation, we have manipulated the canonical Wnt
pathway within the opV placode domain and surrounding ectoderm of chick embryos.
Inhibition of canonical Wnt signaling results in the failure of targeted cells to express or
maintain Pax3 protein, the earliest known specific molecular marker of opV placode
cells. Misexpression of dominant-active β-catenin as an activator of canonical Wnt
signaling, however, is not sufficient to promote the opV placode cell fate. We conclude
that canonical Wnt signaling is necessary for normal opV placode development, and
propose that other molecular cues are required in addition to Wnt signaling to promote
cells to an opV placode fate.

Keywords: ophthalmic trigeminal placode, Wnt, Frizzled, Pax3
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Introduction
In vertebrates, neurogenic placodes, along with a subpopulation of neural crest
cells, contribute sensory neurons to the developing cranial ganglia. While some
neurogenic placodes, such as the otic and olfactory placodes, are thickened regions of
ectoderm that give rise to several derivatives, other neurogenic placodes, including the
trigeminal and epibranchial (geniculate, petrosal, and nodose) placodes, give rise
exclusively to sensory neurons (D'Amico-Martel and Noden, 1983). The development of
these solely neurogenic placodes provides an advantageous model for understanding the
stepwise process of neurogenesis. Our research has focused primarily on the
development of the cutaneous sensory neurons that derive from the ophthalmic trigeminal
placode. The trigeminal ganglion has two main lobes: ophthalmic and
maxillomandibular. These receive neurons from the neural crest and two separate
placodes, the ophthalmic (opV) and the maxillo-mandibular (mmV) placodes. The
placodes contribute neurons to the distal regions of their respective lobes, while the
neural crest contributes neurons to the proximal region of the ganglion. Until the last
decade, research on trigeminal placode induction was not well advanced, primarily due to
the lack of molecular markers for placodal epithelia (Noden, 1993). Stark et al. (1997)
identified the paired-domain/homeodomain transcription factor, Pax3, as the earliest
known gene expressed in the avian opV placode. Using Pax3 as a marker, the tissue
interactions involved in induction and specification of opV placode cells were identified,
and it was shown that a diffusible signal(s) from the dorsal neural tube induces Pax3
expression in the placode (Stark et al., 1997). Explant and grafting experiments
subsequently were performed to better characterize the timing and tissue interactions
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involved in the competence, induction, and specification of the opV placode (Baker et al.,
1999). It was found that the Pax3-inducing signal is present throughout most of the
dorsal neural tube, and that early in development the entire head ectoderm is competent
to form Pax3+ opV placode cells. Similar experiments showed that Pax3 expression in
opV placode ectoderm correlates with specification and commitment to a cutaneous
sensory neuron fate (Baker and Bronner-Fraser, 2000; Baker et al., 2002). While these
studies revealed the cellular and tissue interactions needed for opV placode formation,
the signaling molecules involved in the process were not determined. While other
research has shown, for example, that epibranchial placode induction requires BMPs and
FGFs originating from the pharyngeal endoderm (Begbie et al., 1999), and that FGFs and
Wnt signaling are required for the initial development of the otic placode (Ladher et al.,
2000, 2005; Ohyama et al., 2006), inducing molecules have not been identified for the
trigeminal placodes.
Because we previously showed that opV placode-inducing activity is present in
the dorsal neural tube, we aimed to identify candidate inducing molecules expressed in
this tissue. Multiple Wnt family members, such as Wnt-1, -3a, and -4, can be detected
throughout the neural tube in early chick embryos (Hollyday et al., 1995). Specifically,
Wnt-1 expression begins as early as the 3-somite stage (ss) in the dorsal neural tube. By
the 10ss, expression is found throughout the midbrain, hindbrain, and the future spinal
cord. By 14 somites, expression is restricted to a narrow region in the dorsal midline
encircling the midbrain/hindbrain boundary, directly adjacent to the opV placode.
Furthermore, the Wnt receptors Fz-2 and Fz-7 are expressed in competent cranial
ectoderm in a pattern consistent with a potential role in receiving the opV placode-
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inducing signal (Stark et al., 2000). By the 3ss, Fz-7 is strongly expressed in cranial
ectoderm, becomes restricted to the presumptive trigeminal placode and persists through
the 25ss. At the 3ss, Fz-2 begins to be faintly expressed in the cranial ectoderm and by
the 7-10ss becomes broadly expressed in cranial ectoderm and persists through the 25ss.
There is also correlating evidence from other vertebrate models for Wnt signaling as a
candidate for opV placode induction. In Wnt-1 null and Wnt-1/Wnt-3a double knockout
mice, the opV nerve is considerably reduced, whereas Wnt-3a null mice have normal opV
branching (Ikeya et al., 1997). Furthermore, zebrafish headless mutants, in which Wnt
signaling is over-activated, show a rostral expansion of trigeminal neurons (Kim et al.,
2000). Considering both the functional data from the mouse and zebrafish, and the
Wnt/Fz expression data in the chick, we hypothesized that Wnt signaling is involved in
opV placode cell specification and/or later development.
Wnt/Frizzled signaling has been shown to activate three separate intracellular
pathways. Activation of the canonical cascade leads to cytoplasmic stabilization of βcatenin which translocates to the nucleus and associates with TCF/LEF transcription
factors. The binding of this complex leads to Wnt target gene expression and can lead to
determination of cell fate and differentiation (Veeman et al., 2003). The non-canonical
Wnt pathways include the planar cell polarity pathway, which is involved in cytoskeletal
rearrangements, and the Ca2+ pathway which has been shown to be involved in cell
migration and heart development (Huelsken and Behrens, 2002); (Kuhl, 2004). Because
genetic evidence strongly suggests that Wnt-1 and Wnt-3a signal via the β-catenin
pathway, we focused our efforts on investigating canonical Wnt signaling in opV placode
development. We used dominant-negative Tcf (DN-Tcf) and dominant-active β-catenin
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(DA-βcat) gene expression constructs (Megason and McMahon, 2002) to disrupt and
activate canonical Wnt signaling respectively. These constructs were introduced into
chicken cranial ectoderm using in ovo electroporation at appropriate stages, and the
effects on placode development were examined. We show, through DN-Tcf
misexpression, that competent ectoderm cells require canonical Wnt signaling to adopt
and maintain the opV placode fate. However, we also show that activation of this signal
transduction pathway alone, through DA-βcat misexpression, is not sufficient to promote
competent cells to adopt the opV placode cell fate, nor does it seem to affect the numbers
of cells expressing Pax3 in opV placode ectoderm. More detailed analysis reveals a
possible early and late role for canonical Wnt signaling in opV placode cell fate
determination. Taken together, the data reported here support a requirement for Wnt
signaling in the early steps of opV placode development.

Materials and Methods
Expression reagents
A modified red fluorescent protein (RFP) Wnt reporter electroporation construct,
made by replacing the LacZ gene of the TOPGAL construct (DasGupta and Fuchs, 1999)
with nuclear RFP, was a kind gift from Dr. Andy Groves (House Ear Institute, Los
Angeles). Dominant active human β-catenin and dominant negative human TCF4 (Tetsu
and McCormick, 1999) inserted into the pCIG vector with IRES-nuclear localized green
fluorescent protein (GFP), as well as the pCIG-GFP control vector were a kind gift from
Dr. Andy McMahon (Megason and McMahon, 2002). These expression constructs were
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prepared for electroporation by resuspending at a concentration of 4-8µg/µl in a water
solution containing fast green for visualization.
In ovo electroporation of chicken embryos
The DNA constructs described above were electroporated into 2-14 somite stage
(ss) chicken embryos using standard electroporation techniques, where electrodes were
placed on either side of the embryo, or (most often) using a vertical electroporation
method, where the reference electrode was placed underneath the embryo through a small
hole placed outside the area opaca and the driving electrode was placed directly above the
area of interest (five 10ms pulses of 10V each, one second gap between each pulse; BTX
820 electroporator, Genetronics or four 50ms pulses of 5 V each, one second gap between
each pulse; TSS20 Ovodyne electroporator from Intracel Ltd, Shepreth, UK).
Foil barrier experiments
Following electroporation in 3-6 somite stage embryos, as described above, barriers were
inserted into the head. For placement of barriers, glass needles were used to cut a slit
between the ectoderm and the neural folds and the barriers were inserted with fine
forceps. 7.5 µm thick tantalum foil (Goodfellow #TA000280) was cut into pieces of
approximately 250X350 µm and shaped with fine forceps (Stark et al., 1997). Embryos
were collected after 24 hours and prepared for cryosectioning and immunohistochemical
staining.
Whole-mount in situ hybridization, immunohistochemistry and analysis
Following electroporation, the embryos were incubated 24-48 hours before being
collected and fixed in 4% formaldehyde, and prepared for in situ hybridization or
immunohistochemistry. A chicken Pax3 (Matsunaga, et al., 2001) digoxigenin-labeled
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RNA probe was synthesized and used for whole-mount in situ hybridization on chick
embryos as described by Henrique et al. (1995). For immunohistochemistry, embryos
were embedded in gelatin and cryosectioned to generate12 µm sections of the area of
interest. Sections were mounted on Superfrost® Plus glass slides and the gelatin
removed by treating the slides in phosphate-buffered saline (PBS) at 37°C for 15-20
minutes. Embryo sections were then incubated overnight at 4°C in Pax3 primary antibody
(Baker et al., 1999) diluted 1:300 in antibody buffer (PBS, 0.1% bovine serum albumen,
0.1% triton-X100), followed by incubation for 1 hour in Alexa546- or Alexa488-conjugated
goat anti-mouse IgG2a (Molecular Probes) diluted 1:500 in antibody buffer. Three 5-10
minute washes in PBS followed each incubation. Sections were analyzed using
epifluorescent microscopy; images of Pax3 were overlaid with RFP or GFP images of the
same section in order to observe overlapping expression. For quantitative analysis, five
random sections from the opV (Pax3+) placode/ganglion region of each embryo were
analyzed to minimize variability and bias. Cells positive for Pax3, GFP, or both with a
minimum color threshold were determined using Olympus Microsuite software. Cells
were then counted and statistical analysis performed, with p-values calculated using a
Student’s t-test comparing the standard means of control and experimental samples.

Results
Canonical Wnt signaling is active in Pax3+ opV placode cells
In chick embryos, Pax3 mRNA expression is first seen by in situ hybridization in
ectoderm cells immediately adjacent to the midbrain-level neural folds at the 4-somite
stage (ss) (Stark et al., 1997), while Pax3 protein is first detectable by
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immunohistochemistry at the 7ss, after which the domain of Pax3 expression expands
laterally into the surface ectoderm away from the brain (Baker et al., 1999). In order to
determine whether or not canonical Wnt signaling is active in Pax3+ opV placode cells,
we electroporated a modified RFP version of the TOPGAL Wnt reporter construct,
containing three multimerized LEF/TCF consensus binding sites, into the surface head
ectoderm of 8-11ss chick embryos, aiming for the trigeminal placode region adjacent to
the midbrain and rostral hindbrain. Nuclear RFP should only be expressed in cells in
which the canonical Wnt signaling pathway is active. A day later, at the 26-29ss, RFP
expression was visible in whole-mount embryos in a fairly broad region of head ectoderm
adjacent to the midbrain and rostral hindbrain (Fig. 1 A,E), correlating well with known
domains of Wnt receptor expression (Stark et al., 2000). Electroporated embryos were
subsequently cryosectioned and immunostained for Pax3, which showed that many
RFP+/Pax3+ cells were present in both the opV placode and the forming trigeminal
ganglion (Fig. 1 B-D, F-H). Thus, the canonical Wnt signaling pathway is active in
Pax3+ opV placode cells, as detected by RFP expression within the placodal ectoderm
and in the forming ganglion.
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Figure 1. Canonical Wnt signaling is active in Pax3+ opV placode-derived cells.
(A, E) RFP expression scattered across the head of a 29 somite-stage chick embryo (A)
and a 28 somite-stage chick embryo (E), a day after the RFP Wnt reporter construct was
electroporated into the head ectoderm at the 10-somite-stage. (B-D; F-H) Pax3immunostained sections through the trigeminal ganglion of the embryos in (A) and (E),
respectively, showing bright Pax3+ cells (green; C,D; G,H) in both the opV placodal
ectoderm and in opV placode-derived cells in the forming opV lobe of the trigeminal
ganglion (fainter Pax3+ cells in the ganglion are likely to be neural crest-derived cells).
RFP expression (red; B,D; F,H) co-localizes with Pax3 in both locations (arrows). (ov,
otic vesicle)
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Blocking Wnt signaling in 2-6ss embryos results in cell autonomous loss of Pax3 in
opV placodal ectoderm
Explant and grafting experiments have previously shown that significant numbers
of cells in midbrain-level opV placode ectoderm are specified and committed to express
Pax3 from the 8-9ss onwards (Baker et al., 1999). To determine if Wnt signaling is
necessary for opV placode cell development, we electroporated a dominant-negative
Tcf4-IRES-GFP expression construct (that acts as a constitutive repressor of Wnt targets
due to its inability to bind β-catenin; Megason and McMahon, 2002) into cranial
ectoderm of 2-6ss embryos, before significant Pax3 specification/commitment occurs.
Embryos collected 24 hours after electroporation, at about the 20ss, were prepared for
immunohistochemistry as described, and sections through the opV placode region were
analyzed to identify targeted cells, or cells expressing GFP, within the opV placode
domain ectoderm. In control embryos, electroporation or GFP expression did not appear
to adversely effect placode development, since cells both expressing and lacking Pax3
within the placode domain were found to be targeted, and the placode domain displayed
normal cellular and tissue morphology (Fig. 2A-D). In experimental embryos where DNTcf was expressed concomitantly with GFP, we observed a dramatic loss of GFP+/Pax3+
cells. Further analysis revealed that expression of DN-Tcf resulted in cell-autonomous
inhibition of Pax3, since adjacent (untargeted) cells frequently expressed Pax3 (Fig. 2EH). To quantify this observation, Pax3+, GFP+ and coexpressing cells were counted
from five random sections through the placode domain of each electroporated embryo (in
order to compensate for variation in targeting efficiency, and to avoid experimenter bias),
and statistical analysis was performed as described. In GFP-electroporated control
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embryos (n=8), a mean of 60.4% (s.d. +/- 18.2) of targeted cells in each embryo also
expressed Pax3, while in DN-Tcf-electroporated embryos (n=10), the mean was
dramatically reduced to 3.5% (s.d. +/- 2.5; Fig. 2I). Therefore, blocking canonical Wnt
signaling in the opV placode led to a highly statistically significant reduction of Pax3
expression in targeted cells (p<0.0001).
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Figure 2. Blocking canonical Wnt signaling before significant Pax3 expression
occurs leads to the failure of Pax3 expression in cranial ectoderm
(A-H) In ovo electroporation of pCIG control vector (A-D) or DN-Tcf -pCIG (E-H) in
competent cranial ectoderm. B-D and F-H show magnified view of boxed areas in A and
E respectively. Panels D and H show merged or overlayed images of the adjacent GFP
and Pax3 panels. Embryos underwent electroporation at the 2-6ss and were allowed to
develop for 24hrs to about the 20ss. Sections were analyzed for targeted cells (expressing
GFP, shown in green) and for Pax3 expression to identify opV placode cells (shown in
red). (A-D) Cells targeted with the pCIG control plasmid express GFP, and continue to
express high levels of Pax3 (overlapping cells shown in yellow in panel D). (E-H) GFP+
cells targeted with DN-Tcf show a cell-autonomous loss of Pax3; adjacent untargeted
cells express Pax3 at normal levels. (I) Histogram showing the percentage of targeted
cells expressing Pax3 in control embryos (mean 60.4%, standard deviation [s.d.] 18.2%,
n=8) and DN-Tcf-electroporated embryos (mean 3.5%, s.d. 2.5%, n=10). The dramatic
reduction in Pax3 expression in DN-Tcf-electroporated embryos is highly statistically
significant (p<0.0001). (Arrowheads indicate GFP+ cell; arrows indicate Pax3+ cells,
with co-expressing cells being flanked by both.)
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Blocking Wnt signaling in 2-6ss embryos results in loss of targeted opV placode cells
contributing to the ganglion
To assess the effects of blocking canonical Wnt signaling on the placodal
contribution to the opV ganglion, we electroporated DN-Tcf into 2-6ss embryos, and
allowed them to develop for 48 hours to about the 35ss, when the ganglion is becoming
well-defined. Embryos were analyzed by counting the number of GFP+/Pax3+ cells in
each embryo compared to the total number of Pax3+ cells (targeted and untargeted) in the
ganglion on 5 randomly-selected sections through the opV placode/ganglion region of
each embryo. (Although some neural crest cells express Pax3 at very low levels, opV
placodal Pax3 expression is much higher and thus easily distinguishable from neural crest
expression in migrating cells and in the ganglion.) This analysis allowed us to determine
the proportion of all Pax3+ cells in the ganglion that co-expressed GFP (controls) or
GFP/DN-Tcf (experimentals). Qualitative analysis of these sections showed that after
GFP electroporation, many GFP+ cells contributed to the ganglion (Fig. 3A), while after
DN-Tcf electroporation, nearly all of the GFP+/DN-Tcf expressing cells remained in the
ectoderm, with no contribution to the opV ganglion (Fig. 3B). Cell counts confirmed this:
in control embryos (n=5), the mean percentage per embryo of Pax3+ ganglionic cells that
co-expressed GFP was 47.9% (s.d. +/- 5.2), while in DN-Tcf-electroporated embryos
(n=3), the mean was only 1.1% (s.d. +/- 0.3; Fig. 3C). Thus, electroporating DN-Tcf into
the opV placode at the 2-6 ss led to a highly statistically significant reduction in the
contribution of targeted cells to the ganglion (p<0.005). Importantly, though targeted
cells in experimental embryos did not contribute to the ganglion, and did not express
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Pax3, the opV ganglion was not dramatically reduced in size, and contained many
untargeted Pax3+ placode cells (Fig. 3B).

Blocking Wnt signaling in 10-14ss embryos also results in loss of Pax3 expression and
the failure of targeted opV placode cells to contribute to the ganglion
As described above, significant numbers of cells in midbrain-level opV placode
ectoderm are specified and committed to express Pax3 from the 8-9ss onwards (Baker et
al., 1999). To investigate the effects of blocking Wnt signaling in opV placode cells after
they are specified and/or committed to express Pax3, we electroporated DN-Tcf into the
head ectoderm of 10-14ss embryos and allowed them to develop for 30-36 hours to about
the 35ss, the same stage as the 2-6ss embryos described above that were allowed to
develop for 48 hours. Embryos were quantitatively analyzed in the same way, by
counting the number of GFP+/Pax3+ ganglion cells, compared to the total number of
Pax3+ ganglion cells on 5 randomly-selected sections through the opV placode/ganglion
region of each embryo. Surprisingly, blocking Wnt signaling in older embryos, where
cells are apparently already committed to express Pax3, still led to an inhibition of Pax3
expression and a complete loss of targeted cells contributing to the ganglion (Fig. 4B). In
control embryos (n=5), the mean percentage per embryo of Pax3+ cells that co-expressed
GFP was 39.0% (s.d. +/- 18.8; Fig. 4A,C), while in experimental embryos (n=7), the
mean was only 2.5% (s.d. +/- 3.7; Fig. 4B,C). Thus, electroporating DN-Tcf into the opV
placode at the 10-14ss led to a statistically significant reduction in the contribution of
targeted cells to the ganglion (p<0.02). Importantly, we also observed that the opV
ganglion was significantly reduced in size, with a dramatic reduction in the total number
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of Pax3+ cells (targeted or untargeted) contributing to the ganglion. This effect was not
seen after electroporating DN-Tcf at the 2-6 ss (compare Fig. 4B with Fig. 3B). (Faint
Pax3 staining is still seen in what are presumably neural crest cells in the ganglion.)
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Figure 3. Blocking canonical Wnt signaling before significant Pax3 expression
occurs prevents targeted cells from contributing to the opV ganglion.
Embryos were electroporated with pCIG control vector or DN-Tcf-pCIG between 2-6ss
and collected after 48 hours at about the 35ss. Sections were analyzed for targeted cells
expressing GFP (green) and for expression of the opV placode marker Pax3 (red) in
control (A) or DN-Tcf electroporated embryos (B). (A) GFP+ cells contributed
substantially to the opV ganglion in embryos targeted with pCIG, with numerous cells
expressing both GFP and Pax3 (yellow). (B) In embryos targeted with DN-Tcf, virtually
all GFP+ cells remained in the ectoderm, did not express Pax3, and did not contribute to
the ganglion. However, a significant number of untargeted Pax3+ cells are present in the
ganglion. (C) Histogram showing the percentage of Pax3+ opV ganglion cells that were
also targeted (GFP+) in control (mean 47.9%, s.d. 5.2%, n=5) versus DN-Tcf embryos
(mean 1.1%, s.d. 0.3%, n=3). The dramatic reduction in the contribution of DN-Tcftargeted cells to the ganglion is highly statistically significant (p<0.005).
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Figure 4. Blocking Wnt signaling after significant Pax3 expression prevents targeted
cells from maintaining Pax3 expression and from contributing to the opV ganglion
Embryos were electroporated with pCIG control vector or DN-Tcf-pCIG between 1014ss and collected after 30-36 hours, at about the 35ss. Sections were analyzed for
targeted cells expressing GFP (green) and for expression of the opV placode marker Pax3
(red) in control (A) or DN-Tcf electroporated embryos (B). (A) Cells targeted with the
pCIG vector contribute substantially to the opV ganglion, with numerous cells expressing
both GFP and Pax3 (yellow). (B) Cells targeted with DN-Tcf remain in the ectoderm
rather than contributing to the ganglion, and do not express Pax3. Unlike in embryos
targeted earlier in development (see Fig.3), very few untargeted Pax3+ cells are present
in the ganglion. (C) Histogram showing the percentage of Pax3+ cells within the
ganglion co-expressing GFP in control (mean 39.0%, s.d. 18.8%, n=5) versus DN-Tcf
embryos (mean 2.5%, s.d. 3.7%, n=7) . The dramatic reduction in the contribution of DNTcf-targeted cells to the ganglion is statistically significant mean difference of 36.5%
(p<0.02).
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Activating Wnt signaling does not result in an increase in Pax3+ opV placode cells
To determine if Wnt signaling is sufficient to induce the opV placode cell fate in
cranial ectoderm cells, we electroporated a dominant-active form of β-catenin (DA-βcat),
which is resistant to proteolysis and therefore constitutively activates the Wnt pathway
(Megason and McMahon, 2002), into head and rostral trunk ectoderm of 2-11ss embryos.
After electroporation, embryos were allowed to develop for 24 hours to about the 20ss
before being photographed for GFP expression, and prepared for in situ hybridization or
immunohistochemistry as described. Whole-mount in situ hybridization for Pax3
revealed that the Pax3 expression domain did not expand concomitant with DA-βcat
misexpression, even when ectoderm adjacent to rhombomeres 2-4 (which is competent to
express Pax3 when grafted adjacent to the midbrain; Baker et al., 1999) was targeted
(Figure 5). To confirm this finding, and to determine whether DA-βcat misexpression
biased cells within the placode domain towards Pax3 expression, sections through the
opV placode and adjacent regions were analyzed to identify Pax3+ cells and GFP/DAβcat expressing cells within the ectoderm. Misexpression of DA-βcat in competent
cranial ectoderm did not result in an increase in the number of targeted cells expressing
Pax3 when compared to controls, neither within the placode domain nor in adjacent
ectoderm (Fig. 6A-H). In control embryos (n=10), the mean percentage per embryo of
GFP+ opV placode cells that expressed Pax3 was 66.4% (s.d. +/- 10.8), while in
experimental embryos, the mean was effectively the same, at 68.3% (s.d. +/- 7.7; Fig. 6I).
Therefore, no significant difference between control and experimental embryos was
observed after ectopically activating Wnt signaling in the opV placode domain.
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To rule out the possibility that endogenous placode induction cues were masking
the effect of DA-βcat misexpression (so as to test conclusively that Wnt signaling is not
sufficient to induce Pax3), we blocked signaling from the neural tube using a tantalum
foil barrier (Stark et. al., 1997) and misexpressed DA-βcat in adjacent ectoderm to look
for rescue of Pax3 (n=15). We did not observe a significant rescue of Pax3 in targeted
ectoderm, supporting the conclusion that canonical Wnt signaling is not sufficient for
opV placode induction (Fig. 7).
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Figure 5. Activating Wnt signaling does not expand the opV placodal Pax3
expression domain.
Embryos were electroporated at the 2-11ss with pCIG control vector or dominant active
(DA)-βcatenin-pCIG and allowed to develop 24 hours prior to whole-mount in situ
hybridization for Pax3. (A) Wild-type (WT) embryo showing normal Pax3 expression at
the 22ss. (B-C) Electroporated embryo at the 23ss showing a similar pattern of Pax3
expression (B) even after broad ectodermal targeting with DA-βcat, visualized by
epifluorescent microscopy for GFP (C). (ov-otic vesicle)
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Figure 6. Activating Wnt signaling does not increase the number of Pax3+ cells in
the opV placode
(A-H) In ovo electroporation of pCIG control vector (A-D) or DA-βcat-pCIG (E-H) in
competent cranial ectoderm in 5-9ss embryos, which were allowed to develop 24hrs to
about the 20ss. Sections were analyzed for targeted cells (marked by GFP expression;
green) and expression of Pax3 (red). B-D and F-H show magnified view of white box
highlighted in A and E, respectively. (A-D) Cells targeted with control vector express
GFP. Many cells within the placode domain also express high levels of Pax3
(overlapping cells shown in yellow in D). (E-H) GFP+ cells targeted with DA-βcat are
prevalent, as are cells expressing high levels of Pax3. (I) Histogram showing the
percentage of targeted ectodermal cells expressing Pax3 in control embryos (mean
65.0%, s.d. 11.8%, n=10) and experimental embryos (mean 68.9%, s.d. 7.0%, n=10) .
The difference between the two is not statistically significant. (Arrowheads indicate
GFP+ cells; arrows indicate Pax3+ cells, with co-expressing cells being flanked by
both.)
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Figure 7. Activating Wnt signaling does not rescue loss of Pax3 in opV placode
ectoderm after blocking the Pax3-inducing signal from the brain
Immediately after electroporating 2-6ss embryos with control pCIG or DA-βcat-pCIG,
tantalum foil barriers were placed unilaterally between the neural tube and adjacent
ectoderm to block the diffusible Pax3-inducing signal from the neural tube (as in Stark et
al., 1997). (A) Embryos were collected 24 hours after barrier placement and
photographed to show the location of the barrier. (B) Epifluorescent microscopy
following removal of the barrier shows the extent of the GFP/DA-βcatenin expression
domain. (C) Embryo sections were analyzed for GFP (green) and Pax3 expression (red).
A dramatic reduction in the number of Pax3-expressing opV placode cells lateral to the
barrier was seen, as shown previously (Stark et al., 1997); there was no rescue by DAβcatenin, as evidenced by the many GFP+/Pax3-negative cells lateral to the barrier.
(White line in C indicates barrier location; ov-otic vesicle)
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Discussion
In the late 90s the combined work of Stark et al. (1997) and Baker et al. (1999)
presented data supporting a model for opV placode induction. Through various barrier,
grafting and explant experiments, it was demonstrated that early in development, cranial
ectoderm as far caudal as the first somite is competent to express Pax3 in response to an
inducing signal from the dorsal neural tube. Explant and heterotopic grafting experiments
established the timing of cell specification, showing that a significant number of opV
placode cells within competent ectoderm are specified at the 8ss, with additional cells
being recruited to a placode fate through subsequent stages. Pax3 expression within the
opV cranial ectoderm and underlying mesenchyme crescendos throughout the
developmental process, concomitant with cells upregulating Pax3, entering the
mesenchyme and migrating toward the condensing ganglion, where they maintain Pax3
expression until some point between stage 24 (E4.5) and stage 27 (E5-5.5) (Baker et al.,
2002). While these published works describe the tissue interactions involved in
competence, induction, and specification of the opV placode, the molecules involved in
each differentiation step and their specific functions were not yet identified.
Investigating Wnt signaling in the opV placode using in ovo electroporation to
manipulate intracellular components of the signal transduction pathway allowed us to
obtain cell-autonomous data as to whether canonical Wnt signaling is necessary and
sufficient to promote cells toward a placode fate.
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Canonical Wnt signaling is active in Pax3+ opV placode cells, and is necessary for
Pax3 expression in the placode domain
We show here that canonical Wnt signaling is active in Pax3+ opV placode cells
in the chick embryo, since an RFP Wnt reporter (containing multimerized LEF/TCF
consensus binding sites) is expressed in these cells 24 hours after electroporation of the
reporter into head ectoderm at the 8-11ss. Because LEF/TCF was active in the
developing opV placode, we blocked canonical Wnt signaling prior to the 8ss (before
significant placodal Pax3 expression), by electroporating a dominant negative version of
the canonical Wnt pathway effector TCF (DN-Tcf) into head ectoderm at the 2-6ss and
allowing the embryos to develop for 24 hours to a stage of robust ectodermal Pax3
expression. Gene expression can typically be observed within 2-3 hours after
electroporation (Nakamura et al., 2004). So, the stage at which Wnt signaling is inhibited
after electroporating DN-Tcf at the 2-6ss likely ranges from the 3-8ss. We consistently
observed that dramatically fewer targeted cells in the ectoderm expressed Pax3 in
embryos electroporated with DN-Tcf-IRES-GFP than in embryos electroporated with the
control vector. Importantly, several untargeted cells within the placode domain still
expressed Pax3. From this, we conclude that canonical Wnt signaling is necessary for
Pax3 expression in opV placode cells, and that when ectoderm is targeted prior to the 7ss, untargeted ectoderm cells are still induced to express Pax3.
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Canonical Wnt signaling is necessary for opV placode cells to delaminate and
contribute to the trigeminal ganglion
Based on these initial findings, we assumed that the loss of Pax3 within the opV
ectoderm would also result in a reduction in the total number of placode cells
contributing to the opV ganglion. To test this, we allowed embryos electroporated with
the canonical Wnt inhibitor (DN-Tcf) prior to the 7-somite stage to develop for 48 hours,
when most placode and neural crest cells have reached the condensing ganglion. When
we examined these more developed embryos, we found a statistically significant loss of
targeted cells contributing to the ganglion, showing that blocking Wnt signaling in these
cells indeed prevents their adopting an opV placode cell fate. Instead, many DN-Tcfelectroporated cells were observed in the ectoderm after both 24 and 48 hours. These
cells did not express Pax3, but also showed no signs of apoptosis or necrosis, as the
nuclei and cell structure appeared very similar to cells in control embryos. In addition,
the overall number of targeted cells did not appear dramatically reduced, and the
ectodermal tissue in the targeted area was similar histologically to that observed in
control embryos. Therefore, targeted cells remained in the ectoderm and did not undergo
the processes of delamination, migration or ganglion condensation (as evidenced by a
lack of GFP+ cells in the mesenchyme). While the opV ganglia were somewhat reduced
in size to varying degrees in these embryos, the overall morphology was not grossly
affected, since we observed a reasonable number of untargeted Pax3+ opV placodederived cells within the ganglion. These results therefore provide evidence that
significant compensation occurs from untargeted cells within or adjacent to the placode
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field that are induced to express Pax3, to allow a sufficient contribution of opV placode
cells to the ganglion.
To summarize, after blocking canonical Wnt signaling, targeted cells were
excluded from the placode pool. These cells remained within the ectoderm and, had
development proceeded, we suggest they would most likely have adopted an epidermal
fate. These data, taken together, support the hypothesis that canonical Wnt signaling
plays an important role very early in determining opV placode cell fate and
distinguishing opV placode cells from adjacent epidermal ectoderm cells. This is
reminiscent of what has been observed in the otic placode, where Wnt signaling acts to
regulate the choice between an otic placode and an epidermal fate (Ohyama et al., 2006;
see later).

Canonical Wnt signaling is necessary for continued maintenance of Pax3 in opV
placode development
After the 8ss stage, a substantial number of opV placode cells become specified
and committed to express Pax3 and to contribute cutaneous sensory neurons to the opV
trigeminal ganglion, as determined by explant and heterotopic grafting experiments
(Baker et al., 1999). However, the committed nature of these cells has not previously
been tested under conditions where canonical Wnt signaling is blocked. To determine if
Wnt signaling remains necessary after the time of initial Pax3 expression, we performed
the same Wnt inhibition experiments in 10-14ss embryos. Because a significant number
of opV placode cells would already be expressing Pax3 at the time of electroporation, and
would therefore be characterized as committed to a cutaneous sensory neuron fate, we
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expected to see many targeted cells expressing Pax3 and contributing to the ganglion.
Surprisingly, we observed the opposite. Blocking Wnt signaling in older embryos
resulted in a loss of targeted cells contributing to the ganglion, much like what was
observed in embryos targeted prior to the 7ss. Again, DN-Tcf-expressing cells remained
in the ectoderm and did not express Pax3. By inhibiting canonical Wnt signaling late,
therefore, we were able to alter the fate of opV placode cells that were already specified,
and apparently committed, to the placode cell fate. Therefore, these data clearly suggest
a requirement for canonical Wnt signaling after Pax3 is already expressed in opV placode
cells, not only to maintain Pax3 expression, but also to allow delamination and
contribution to the ophthalmic lobe of the trigeminal ganglion. We conclude that
continued Wnt signaling is needed for maintenance of the opV placode cell fate and
further differentiation.

Ectodermal plasticity diminishes after DN-Tcf electroporation at the 10-14ss
Although DN-Tcf-targeted cells remained in the ectoderm and did not express
Pax3 in either the early (2-6ss) or late (10-14ss) Wnt inhibition experiments, there was a
significant reduction in the total number of untargeted Pax3+ placode cells contributing
to the ganglion after electroporation at later stages. In early embryos, significant
compensation occurred from untargeted cells, as evidenced by adequate placodal
contribution to the ganglion. Blocking Wnt signaling in 10-14ss embryos, however,
resulted in a loss of compensation from untargeted cells, as evidenced by a significant
decrease in the number of Pax3+ placode cells contributing to the ganglion. After late
targeting, it appears that Pax3+ placode cells must lose Pax3 expression and their ability
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to contribute to the ganglion. In addition, neighboring untargeted cells do not
compensate, indicating that either they have lost competence to express Pax3, or that the
Pax3-inducing signal is no longer present when Wnt activity is blocked. Some support
for the later hypothesis is provided by previous grafting experiments, which suggested
that the Pax3-inducing signal at the midbrain level may decline after the 8ss (Baker et al.,
1999). This is well before the stage at which Wnt signaling is blocked in this study,
which is likely to be 2-3 hours after electroporation, perhaps at the 12-16ss. Conversely,
sufficient inducing activity must be present (perhaps from the rostral hindbrain or
midbrain/hindbrain junction) through at least the 12ss, since previous ablation
experiments showed that when presumptive opV placodal ectoderm in 12ss embryos was
removed and embryos were allowed to develop to a stage of ganglion condensation, opV
placode cells were still present, albeit reduced in number, with the majority of remaining
cells condensing external to the ganglion (Stark et al., 1997). Alternatively (if the
inducing signal is present at these later stages), the competence of untargeted ectoderm
cells in this region to respond to the Pax3-inducing signal may be lost. In either case, our
results suggest that, by the time Wnt signaling is blocked after electroporation at the 1014ss, much of the cellular plasticity of opV cranial ectoderm is lost. Cells within the opV
placode domain and nearby ectoderm have adopted either an opV placodal or epidermal
fate, and no more Pax3+ cells are generated, with the placode fate being maintained by
canonical Wnt signaling.
Given that Wnt signaling is required to maintain Pax3 expression and,
presumably, the opV placode cell fate, how then can we explain the previous
specification and commitment data obtained through explant and heterotopic grafting
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experiments (Baker et al., 1999)? The data presented here would predict that Pax3+ opV
ectoderm cells would lose Pax3 expression in neutral culture conditions (specification
test), and possibly after grafting to a heterotopic location (commitment test, in this case,
grafting over the lateral plate mesoderm; Baker et al., 1999), unless Wnt signals were
present in the grafted location. There are at least two possible explanations for the
specification test. First, Wnts may be expressed in the explanted ectoderm, thus signaling
in an autocrine fashion would result in maintenance of Pax3 expression. Second, in the
absence of other factors normally produced by nearby embryonic tissues, cells would
continue down whatever specified fate was in place at the time of experimentation. In
other words, Wnt would no longer be required for maintenance of the opV placode fate,
since the tissue is no longer receiving alternative specification cues normally found in the
embryonic environment. Future experiments aimed at examining the expression of Wnt
family members, and the response of cranial ectoderm tissue to various candidate
signaling factors, will resolve this question.

Canonical Wnt signaling is not sufficient to induce an opV placode cell fate
Several Wnt molecules are expressed in tissue capable of inducing the opV
placode. To test whether activating canonical Wnt signaling is sufficient for opV placode
induction, we electroporated DA-βcat into a broad domain of cranial ectoderm at the 59ss, when ectoderm is competent to upregulate Pax3, and during the time of peak
placodal induction. We found that there was not a significant increase in the number of
targeted cells expressing Pax3 in the ectoderm, either within the opV placode domain or
in nearby ectoderm, indicating that Wnt signaling alone is not sufficient for induction of
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an opV placode fate. Even when a barrier was placed between the neural tube and
ectoderm to block endogenous inductive signaling, misexpression of DA-βcat was not
able to rescue placodal loss. While initially surprising to us, it is not inconsistent with
results aimed at identifying inducing signals for other placodes. For example, it has been
shown that initial otic placode development requires combined Wnt and Fgf signals
(Ladher et al., 2000, 2005). Clarifying these results, Ohyama et al. (2006) presented data
from mouse embryos in which Wnt signaling was genetically activated or inhibited
specifically in Pax2+ cells. They proposed a model wherein Fgf signaling specifies a
domain of Pax2 expressing cells, and subsequent Wnt signaling influences the fate choice
of these cells, by promoting the otic placode fate over epidermis (Ohyama et al., 2006).
Wnt signaling in otic placode development also has an important later function, along
with Sonic Hedgehog, in patterning (reviewed by Brigande et al., 2000; Fekete and Wu,
2002; Ohyama et al., 2006). While the opV placode is much simpler than the otic
placode, where multiple derivatives arise and complex patterning takes place, it is
nonetheless unlikely to require only a single signal for proper cell specification. The data
presented here support this model, since we show that canonical Wnt signaling is
required for adoption of the opV placode cell fate, but is not itself sufficient to induce
competent cells toward that same fate.
Since canonical Wnt signaling is not sufficient for opV placode induction, is it
possible that it functions only in specified cells as a general mechanism for maintaining
or further promoting placodal cell fate? One possible model is that canonical Wnt
signaling acts as a downstream “lock-in” step for Pax3+ cranial ectoderm cells,
stabilizing Pax3 expression and enabling cells to adopt their specified fate. This is the
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model proposed for Pax2+ cranial ectoderm cells, which require Wnt signaling to adopt
an otic placode rather than epidermal fate (Ohyama et al., 2006). This commonality raises
the intriguing possibility that Wnt signaling plays a similar role in the initial stages of the
development of other placodes. This is also consistent with the model proposed by
Martinez-Arias and Hayward (2006), in which Wnt signaling stabilizes and maintains
gene expression during cell fate transitions and other developmental processes, enabling
the adoption of specific cell fates.
Alternatively, Wnts may play a dual role in opV placode cell specification. First,
the dorsal neural tube emits a canonical Wnt signal, in conjunction with other signal(s),
such as FGF or BMP, which act together to induce or specify competent ectoderm to the
Pax3-expressing opV placode fate. Subsequently Wnts, either from within the cranial
ectoderm or adjacent tissue, act to maintain Pax3 expression and the opV placode cell
fate until cellular differentiation. Similar multi-step requirements for Wnt signaling
occur in other developmental systems, such as in the developing somites. It has been
shown by multiple groups that Wnt1/3a in the dorsal neural tube act to induce Wnt11
expression in the medial dermomyotome. Wnt11 expression is necessary for maintaining
the state of those cells, while Wnt6 from the overlying ectoderm acts on more lateral
dermomyotome cells. While Wnt1/3a act to induce Wnt11, Wnt11 and Wnt6 act as
epithelialization factors necessary for continued dermomyotomal development (Marcelle
et al., 1997; Schmidt et al., 2000; Schmidt et al., 2004; Linker et al., 2005; GeethaLoganathan et al., 2006). In addition, Wnt5b expression from within the segmental plate
mesoderm is thought to play a role in initial myogenic differentiation (Linker et al.,
2003). In support of a model where Wnt signaling acts synergistically with another
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factor to induce the opV placode, Wnt-deficient mice have a reduced opV nerve (Ikeya et
al., 1997).
Conclusions
The stepwise process of cell fate determination is often a complex process of cellcell signaling and continued fate restriction. While the tissue interactions required for
opV placode development have been known for some time through classical
embryological experiments, the molecules involved in the process have eluded discovery.
We have demonstrated that canonical Wnt signaling is required for cells to adopt the opV
placode cell fate, and must be maintained for their continued differentiation. Canonical
Wnt signaling however is not sufficient, since activating this signal transduction pathway
alone does not promote cells toward an opV placode fate. The specification of these
cells, therefore, requires additional signals, which remain elusive. Future studies will aim
to identify the additional molecular cues that must be involved in opV placode induction
and differentiation.
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Table 1. DN-Tcf 2-6ss 24hr Placode Cell Counts
Experimental Embryos
Embryo
1

Total
2

Total
3

Total
4

Total
5

Total
6

Total
7

Total
8

Total
9

Total

Date
3.4.2005
3.4.2005
3.4.2005
3.4.2005
3.4.2005
3.4.2005
5.20.2005
5.20.2005
5.20.2005
6.17.2005
6.17.2005
6.17.2005
6.17.2005
6.17.2005
6.17.2005
6.28.2005
6.28.2005
6.28.2005
2.23.2006
2.23.2006
2.23.2006
2.23.2006
2.23.2006
2.23.2006
2.23.2006
2.23.2006
2.23.2006

G+/P+
0
0
0
0
1
2
1
4
1
0
0
1
1
1
0
2
0
0
0
0
0
0
1
1
2
0
0
2
1
1
0
2
0
0
1
1

G+/P2
6
5
13
12
18
24
54
41
33
13
87
20
44
13
77
14
11
6
31
7
12
7
26
13
17
9
39
5
12
14
31
6
6
10
22

73

Total G+

% (G+P+/TotG+)

13

0.000

58

6.897

88

1.136

79

2.532

31

0.000

27

3.704

41

4.878

33

6.061

23

4.348

Table 1. DN-Tcf 2-6ss 24hr Placode Cell Counts (continued)
Embryo
10

Date
2.23.2006
2.23.2006
2.23.2006

Total

G+/P+
0
2
0
2

G+/P10
12
13
35

Total G+

% (G+P+/TotG+)

37

5.405

G+/P18
8
16
42
6
4
3
13
0
1
3
4
3
6
1
10
3
11
1
15
2
6
3
11
4
1
2
7
2
4
4

Total G+

% (G+P+/TotG+)

62

32.258

23

43.478

16

75.000

26

61.538

47

68.085

48

77.083

37

81.081

Control Embryos
Embryo
Date
1
3.23.2005
3.23.2005
3.23.2005
Total
2
3.23.2005
3.23.2005
3.23.2005
Total
3
6.8.2005
6.8.2005
6.8.2005
Total
4
6.17.2005
6.17.2005
6.17.2005
Total
5
2.23.2006
2.23.2006
2.23.2006
Total
6
2.23.2006
2.23.2006
2.23.2006
Total
7
2.23.2006
2.23.2006
2.23.2006
Total
8
2.23.2006
2.23.2006
2.23.2006

G+/P+
10
3
7
20
4
2
4
10
7
2
3
12
7
5
4
16
10
13
9
32
21
12
4
37
10
10
10
30
2
3
3
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Total
8
10
Table 2. DN-Tcf 2-6ss 24hr Statistical Analysis

18

t-Test for Two Sample Means From Different Populations
Ho: No Difference, i.e., Difference is Not Significant
Control

Experimental

Sample Size

8

10

Sample Mean

60.37050

3.49600

Sample Std Dev

18.17600

2.48100

Degrees of Freedom = 7
Difference of Means = 56.87
t = 8.785

p = 0.000050

α = 0.050

95% Confidence Interval: 41.57 to 72.18

t* = 2.3646
Reject Ho
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44.444

Table 3. DN-Tcf 2-6ss 48hr Ganglion Cell Counts
Experimental Embryos
Embryo
Date
1
2.10.2006
2.10.2006
2.10.2006
2.10.2006
2.10.2006
Total
2
2.10.2006
2.10.2006
2.10.2006
2.10.2006
2.10.2006
Total
3
2.22.2006
2.22.2006
2.22.2006
2.22.2006
2.22.2006
Total

G+/P+
0
0
0
0
1
1
0
0
0
1
0
1
0
1
0
0
0
1

P+
12
16
30
23
10
91
12
19
12
10
14
67
29
29
20
20
27
125

Tot P+

% (G+P+/Totp+)

92

1.087

68

1.471

126

0.794

Embryo
Date
G+/P+
1
2.22.2006
22
2.22.2006
33
2.22.2006
38
2.22.2006
40
2.22.2006
4
Total
137
2
2.22.2006
11
2.22.2006
13
2.22.2006
12
2.22.2006
10
2.22.2006
6
Total
52

P+
24
33
44
50
3
154
6
12
8
8
7
41

TotP+

% (G+P+/Totp+)

291

47.079

93

55.914

Control Embryos
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Table 3. DN-Tcf 2-6ss 48hr Ganglion Cell Counts (continued)
Embryo
Date
G+/P+
3
2.22.2006
3
2.22.2006
15
2.22.2006
16
2.22.2006
21
2.22.2006
13
Total
68
4
3.28.2006
27
3.28.2006
40
3.28.2006
23
3.28.2006
37
3.28.2006
23
Total
150
5
3.28.2006
6
3.28.2006
12
3.28.2006
15
3.28.2006
7
3.28.2006
4
Total
44

P+
2
9
23
20
14
68
56
55
31
25
25
192
12
12
10
18
6
58

Tot P+

% (G+P+/TotP+)

136

50.000

342

43.860

102

43.137
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Table 4. DN-Tcf 2-6ss 48hr Ganglion Statistical Analysis
t-Test for Two Sample Means From Different Populations
Ho: No Difference, i.e., Difference is Not Significant
Control

Experimental

Sample Size

5

3

Sample Mean

47.90000

1.12000

Sample Std Dev

5.20000

0.33800

Degrees of Freedom = 2
Difference of Means = 46.78
t = 20.046

p = 0.0025

α = 0.050

t* = 4.3027

95% Confidence Interval: 36.74 to 56.82 Reject Ho
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Table 5. DN-Tcf 10-14ss 30-36hr Ganglion Cell Counts
Experimental Embryos
Embryo
Date
1
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
Total
2
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
Total
3
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
Total
4
3.1.2006
3.1.2006
3.1.2006
3.1.2006
3.1.2006
Total
5
3.1.2006
3.1.2006
3.1.2006
3.1.2006
3.1.2006
Total

G+/P+
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
1
0
0
0
1

P+
2
1
1
1
5
10
1
0
0
2
8
11
16
6
13
19
9
63
6
5
8
7
9
35
3
1
1
1
5
11

Tot P+

% (G+P+/TotP+)

10

0.000

11

0.000

64

1.563

35

0.000

12

8.333
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Table 5. DN-Tcf 10-14ss 30-36hr Ganglion Cell Counts (continued)
Embryo
Date
6
3.3.2006
3.3.2006
3.3.2006
3.3.2006
3.3.2006
Total
7
3.3.2006
3.3.2006
3.3.2006
3.3.2006
3.3.2006
Total

G+/P+
0
0
0
0
0
0
0
1
1
0
0
2

P+
0
12
4
4
0
20
4
12
7
0
2
25

Tot P+

% (G+P+/TotP+)

20

0.000

27

7.407

G+/P+
7
19
16
12
6
60
6
10
11
4
3
34
2
5
5
5
5
22

P+
4
8
9
11
6
38
5
4
5
7
6
27
23
20
18
25
21
107

Tot P+

% (G+P+/TotP+)

98

61.224

61

55.738

129

17.054

Control Embryos
Embryo
1

Total
2

Total
3

Total

Date
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
9.4.2005
3.3.2006
3.3.2006
3.3.2006
3.3.2006
3.3.2006
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Table 5. DN-Tcf 10-14ss 30-36hr Ganglion Cell Counts (continued)
Embryo
4

Total
5

Total

Date
3.3.2006
3.3.2006
3.3.2006
3.3.2006
3.3.2006
3.28.2006
3.28.2006
3.28.2006
3.28.2006
3.28.2006

G+/P+
4
9
12
13
5
43
11
20
24
12
13
80

P+
10
20
21
26
20
97
30
37
55
40
26
188

Tot P+

% (G+P+/TotP+)

140

30.714

268

29.851
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Table 6. DN-Tcf 10-14ss 30-36hr Ganglion Statistical Analysis
t-Test for Two Sample Means From Different Populations
Ho: No Difference, i.e., Difference is Not Significant
Control

Experimental

Sample Size

5

7

Sample Mean

39.00000

2.47000

Sample Std Dev

18.70000

3.74000

Degrees of Freedom = 4
Difference of Means = 36.53
t = 4.307

p = 0.0126

α = 0.050

95% Confidence Interval: 12.98 to 60.08

t* = 2.7764
Reject Ho
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Table 7. DA-βcat 5-9ss 24hr Placode Cell Counts
Experimental Embryos
Embryo
Date
G+/P+ G+/P1
11.8.2005
5
3
11.8.2005
8
4
11.8.2005
8
3
11.8.2005
4
1
11.8.2005
3
0
Total
28
11
2
1.13.2006
14
8
1.13.2006
20
3
1.13.2006
29
22
1.13.2006
7
4
1.13.2006
12
5
Total
82
42
3
1.13.2006
15
10
1.13.2006
10
8
1.13.2006
10
8
1.13.2006
9
10
1.13.2006
13
3
Total
57
39
4
1.13.2006
15
3
1.13.2006
11
8
1.13.2006
20
5
1.13.2006
13
4
1.13.2006
11
15
Total
70
35
5
1.13.2006
22
3
1.13.2006
17
4
1.13.2006
18
10
1.13.2006
16
3
1.13.2006
16
7
Total
89
27
6
1.23.06
11
3
1.23.06
12
1
1.23.06
9
3
1.23.06
13
3
1.23.06
9
3
Total
54
13

Total G+

% (G+P+/TotG+)

39

71.795

124

66.129

96

59.375

105

66.667

116

76.724

67

80.597
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Table 7. DA-βcat 5-9ss 24hr Placode Cell Counts (continued)
Embryo
7

Total
8

Total
9

Total
10

Date
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06
1.23.06

Total

G+/P+ G+/P13
5
17
1
14
10
20
3
5
3
69
22
7
6
17
4
8
9
3
1
2
3
37
23
11
4
6
4
10
9
13
4
8
5
48
26
9
6
8
4
6
1
6
5
9
4
38
20

Total G+

% (G+P+/TotG+)

91

75.824

60

61.667

74

64.865

58

65.517

Control Embryos
Embryo
Date
1
11.8.2005
11.8.2005
11.8.2005
11.8.2005
11.8.2005
Total

G+/P+
7
11
7
6
4
35

G+/P16
17
14
7
8
62
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Total G+

% (G+P+/TotG+)
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36.082

Table 7. DA-βcat 5-9ss 24hr Placode Cell Counts (continued)
Embryo
Date
2
1.13.2006
1.13.2006
1.13.2006
1.13.2006
1.13.2006
Total
3
1.13.2006
1.13.2006
1.13.2006
1.13.2006
1.13.2006
Total
4
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
Total
5
1.13.2006
1.13.2006
1.13.2006
1.13.2006
1.13.2006
Total
6
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
Total
7
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
Total

G+/P+
5
32
26
20
20
103
10
12
24
16
12
74
29
19
23
16
8
95
9
13
8
12
18
60
7
7
8
10
10
42
8
7
8
5
6
34

G+/P3
14
4
6
22
49
6
6
5
12
6
35
1
4
11
9
7
32
4
10
11
9
2
36
8
2
4
4
7
25
1
3
4
6
10
24
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Total G+

% (G+P+/TotG+)

152

67.763

109

67.890

127

74.803

96

62.500

67

62.687

58

58.621

Table 7. DA-βcat 5-9ss 24hr Placode Cell Counts (continued)
Embryo
8

Total
9

Total
10

Total

Date
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06
1.20.06

G+/P+
2
17
20
18
25
82
17
14
15
10
4
60
20
14
14
13
15
76

G+/P3
9
6
9
7
34
5
4
9
5
3
26
6
2
2
4
6
20

Total G+

% (G+P+/TotG+)

116

70.690

86

69.767

96

79.167
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Table 8. DA-βcat 5-9ss 24hr Statistical Analysis
t-Test for Two Sample Means From Different Populations
Ho: No Difference, i.e., Difference is Not Significant
Control

Experimental

Sample Size

10

10

Sample Mean

66.44

68.31

Sample Std Dev

10.34

7.65

Degrees of Freedom = 9
Difference of Means = -1.87
t = -0.459

p = 0.6569

α = 0.050

95% Confidence Interval: -11.07 to 7.33

t* = 2.2622
Do Not Reject Ho
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Chapter 3
Co-factors in opV Placode Induction
Introduction
In light of recent findings, which suggest that Wnt signaling is necessary but not
sufficient for cell fate determination in the opV placode, many new questions have
emerged. Among these are: Which Wnt ligand is involved in signaling from the neural
tube to the cranial ectoderm? Is Wnt signaling directly influencing opV placode induction
or involved only in maintenance? What other signaling molecules are working prior to or
as co-factors with Wnts to induce Pax3 expression in the placode? We have started to
answer these questions with follow-up experiments included in this chapter, along with
other experiments currently planned and being performed.
As mentioned in previous chapters, multiple Wnts are expressed in the dorsal
neural tube that may be responsible for expression and maintenance of Pax3 in the opV
placode. Spatiotemporal expression patterns suggest that the most likely candidates are
Wnt-1 and Wnt-3a, however functional data in the mouse indicates that Wnt-1 may play
a direct role in the development in the opV branch of the trigeminal ganglion. Though
Wnt-1, Wnt-3a, and Wnt-1/3a double knockout mice have been analyzed for
morphological differences in the CNS and cranial ganglia, showing a reduced opV
branch in both the Wnt-1 and double knockout mice, analysis of these mice early in
development has not been published. The next aim was to obtain the Wnt knockout mice
and analyze Pax3 expression to determine if Wnt-1, Wnt-3a, or both play a role in opV
placode induction. Fortunately, our collaborator, Dr. Jeff Barrow, was currently breeding
Wnt-3a mice. We were able to readily obtain Wnt3a null mice and analyze them for Pax3
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protein expression in placodal ectoderm. The Wnt-1 mice have just recently been
obtained; as of this time they are quarantined and have not yet been analyzed.
We next addressed the possibility that other signals may be playing a role in early
opV placode development. Both FGFs and BMPs are located in the dorsal neural tube
and may be involved in determination of placode cell fate. Experiments performed in the
otic placode utilized the general FGF receptor chemical inhibitor, SU5402, to determine
whether FGF signaling was involved in early induction of the otic placode (Martin and
Groves, 2005). Explant head cultures revealed that inhibition of FGF signaling resulted in
loss of two otic placode markers, including Pax2. Following this finding, they performed
multiple ectoderm explant experiments treated with twelve different FGFs and discovered
that presumptive otic ectoderm responded only to FGF2. FGF2 was sufficient to induce
most otic markers including Pax2. Interestingly, they also exposed presumptive
trigeminal ectoderm of 0-4ss embryos (prior to expression of the FGFR4 receptor known
to be a marker of the opV placode) to FGF2, which also resulted in upregulation of Pax2
thereby altering the fate of opV placode cells. This suggests that there may be
uncharacterized FGF receptors in the presumptive trigeminal ectoderm that were able to
respond to the FGF2 signal. Because of this likely possibility, experiments were next
focused on investigating the role of FGFs in opV placode development.

90

Materials and Methods
Wnt-3a Knockout Mice
Mice homozygous for the Wnt3a allele (Takada, 1994) were obtained from Dr.
Jeffery Barrow (special thanks to the Barrow lab for the breeding and upkeep of the
mice). Mice were collected at day E8.5 and fixed in 4% formaldehyde. Embryos were
cryosectioned and immunostained for the presence of Pax3.

Immunohistochemistry
Prior to antibody staining, embryos were embedded in gelatin and cryosectioned
to generate 12 µm sections of the area of interest. Sections were mounted on Superfrost®
Plus glass slides and the gelatin removed by treating the slides in phosphate-buffered
saline (PBS) at 37°C for 15-20 minutes. Embryo sections were then incubated overnight
at 4°C in Pax3 primary antibody (Baker et al., 1999) diluted 1:200 in antibody buffer
(PBS, 0.1% bovine serum albumen, 0.1% triton-X100), followed by incubation for 1 hour
in Alexa546-conjugated goat anti-mouse IgG2a (Molecular Probes) diluted 1:500 in
antibody buffer. Three 5-10 minute washes in PBS followed each incubation. Sections
were analyzed using epifluorescent microscopy.

Explant Head Cultures
Head regions comprising the prospective trigeminal placode ectoderm were dissected
from 2-6ss embryos using a micro-scalpel. Tissues were stored in complete medium on
ice (10% fetal bovine serum, 15% chick embryonic extract in DMEM) until required,
then rinsed in sterile DMEM before transplanting into collagen gels. Collagen matrix gels
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were prepared as previously described (Groves and Bronner-Fraser, 2000). Briefly, 90 µl
of rat tail collagen and 10 µl of 10X DMEM were combined. A few drops of 7.5%
sodium bicarbonate were added to adjust the pH to 7.5. For head region cultures, 20 µl
drops of the prepared collagen solution were plated and allowed to set. DMEM (1 ml)
with N2 supplement (GIBCO) was added with either SU5402 or DMSO vehicle (adapted
from Martin and Groves, 2005). Slits were cut in the gel, and the heads slipped in.
Cultures were grown at 37°C and 5% CO2 for 24 hours. Cultures were fixed in 4%
paraformaldehyde overnight at 4°C and prepared for cryosection. Sections were then
immunostained and analyzed for Pax3 protein.

Results
Wnt3a knockout mice retain normal Pax3 expression in opV placodal ectoderm
Wnt gene expression data in the chick neural tube indicate a role for the Wnt/Fz
signaling pathway in early opV placode induction and development. Functional data in
Wnt knockout mice lend support to this hypothesis. Wnt-1 and Wnt-3a null mice were
obtained and Wnt-3a (-/-) mice (Takada, 1994) were analyzed for expression of Pax3
protein (Wnt-1(-/-) mice were delayed indefinitely and are currently quarantined at BYU).
Wnt-3a (-/-) mice were collected at day E8.5, fixed in 4% formaldehyde and prepared for
cryosection. Embryo sections were immunostained for Pax3 protein. Pax3 expression in
trigeminal placodal ectoderm appeared normal (Fig. 1). Pax3 cells were also seen
beginning to migrate into the mesenchyme (Fig. 1C). No obvious reduction in Pax3
protein was observed in Wnt-3a (-/-) mice.
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Inhibiting FGF signaling in presumptive placodal ectoderm explants prevents Pax3
expression in the opV placode
Studies in otic placode induction (Martin and Groves, 2005) showed that
presumptive trigeminal ectoderm will respond to the FGF2 protein signal by upregulating
the otic placode marker Pax2. This result suggests that presumptive trigeminal ectoderm
may have uncharacterized FGF receptors that may be involved in opV placode induction.
To test this hypothesis, the general FGF receptor chemical inhibitor, SU5402, was used to
block FGF signaling in head explant cultures. The head region, encompassing the
midbrain and rostral hindbrain, was dissected from 2-6ss chick embryos and cultured in a
collagen matrix with either SU5402 or DMSO. Explants were incubated for 24hrs, then
fixed in 4% formaldehyde O/N, and prepared for cryosection. Immunohistochemistry was
performed on the sections to evaluate Pax3 expression in placodal ectoderm. Stained
sections were then visualized by fluorescent microscopy and images were taken of all
sections in the head region for qualitative analysis. Quantitative analysis was performed
on five random sections and ectoderm cells positive for Pax3 were counted. Control
explants exposed to DMSO had a sample mean of 187.3 (s.d. +/- 30.0) total Pax3+ cells
(n=3, see Table 1; Fig. 2A). Experimental SU5402 explant cultures had a sample mean of
31.3 (s.d. +/- 18.0) total Pax3+ cells (n=3, Table 1; Fig. 2B,C). This resulted in a
statistically significant difference of 156.0 with p=0.016, suggesting that FGF signaling
may play a role in early opV placode cell fate (Table 2; Fig. 2D).
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Figure 1. Pax3 Analysis of Wnt-3a Null Mice
Normal Pax3 expression is present in Wnt-3a(-/-) mice. Mice were collected at day E8.5.
(A) Pax3 is seen in neural folds and is beginning to be expressed in ectoderm. (B) Cranial
ectoderm expression of Pax3. (C) Pax3 is expressed in neural folds, cranial ectoderm, and
is also present in the mesenchyme.
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Figure 2. FGF SU5402 Inhibition Head Cultures
Inhibiting FGF signaling in head explants results in reduction of the opV placode marker
Pax3. (A) Midbrain level head explant incubated in DMSO shows high level Pax3
expression in cranial ectoderm. (B,C) Explants incubated in the FGF receptor chemical
inhibitor, SU5402, show dramatic reduction of Pax3 expression in cranial ectoderm. (D)
Histogram depicting total Pax3+ cells in the ectoderm counted from 5 random sections.
Control explants exposed to DMSO had a sample mean of 187.3 (s.d. +/- 30.0) and
experimental SU5402 explant cultures had a sample mean of 31.3 (s.d. +/- 18.0) total
Pax3+ cells. This resulted in a statistically significant difference of 156.0 with p=0.016.
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Discussion
Wnt-3a is not necessary for opV placode induction
Wnt expression data in the chick indicate a possible role for Wnt/Fz signaling in
early opV placode induction. Studies focused on manipulating the canonical Wnt
pathway at the intracellular level showed that Wnt signaling is necessary for Pax3
expression in the opV placode. To determine which specific Wnt ligand(s) are
functioning in opV placode induction, we attempted to analyze the most likely
candidates, Wnt-1 and Wnt-3a, by analyzing knockout mice. Wnt-1 and Wnt-1/3a double
knockout mice result in a reduced ophthalmic branch of the trigeminal ganglia, whereas
Wnt-3a(-/-) do not. As expected, analysis of Wnt-3a null mice confirmed that Wnt-3a is
not necessary for placodal induction showing no obvious reduction of Pax3 in the opV
placode. Analysis of Wnt-1 mice is currently planned and will be undertaken as soon as
mice are readily available.

FGF signaling is necessary for early opV placode cell development
Recent findings show a role for Wnt signaling in early opV placode development.
Although Wnt was found to be necessary for expression of the Pax3 opV marker, it was
not sufficient to induce competent cranial cells to this same fate. This supports the
hypothesis that additional signaling factors are needed for induction of the opV placode.
Both FGFs and BMPs are found in the dorsal neural tube and may be involved in this
process. The FGF receptor FGFR4 is a known marker of the opV placode but does not
become expressed until after Pax3 at approximately the 10ss. But recent data revealed
that presumptive trigeminal ectoderm from 0-4ss embryos is responsive to the otic
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placode inducer FGF2 and will take on an otic fate by expressing Pax2. This indicates
that there may be uncharacterized FGF receptors expressed earlier in competent
ectoderm. It is also possible that different FGF ligands can influence early decisions that
separate common placodal ectoderm into distinct placodes such as otic or trigeminal. To
investigate this possibility, we needed to determine if FGF signaling is necessary for opV
placode cell fate. Using the FGF receptor chemical inhibitor, SU5402, we blocked FGF
signaling in head explants. Blocking FGF signaling in explant head cultures, of 2-6ss
embryos, resulted in a statistically significant reduction of Pax3 expressing cells in
placodal ectoderm when compared to DMSO control explants. This suggests that FGF
signaling is indeed necessary for Pax3 expression and early opV placode cell
determination and development. From this we can propose a model whereby Wnts and
FGFs work synergistically to specify the opV placode cell fate. Additional experiments
will expose naïve cranial ectoderm to different Wnt and FGF signals together in attempt
to induce the opV placode cell fate.
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Table 1. FGF Inhibitor SU5402 Cell Counts
Experimental Embryos
Embryo
1

Total
2

Total
3

Date
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
5.09.06
5.09.06
5.09.06
5.09.06
5.09.06

Total

Pax3+
21
7
4
0
0
32
22
15
7
2
3
49
0
2
2
1
8
13

Control Embryos
Embryo
1

Total
2

Total

Date
6.01.06
6.01.06
6.01.06
6.01.06
6.01.06
Total
5.18.06
5.18.06
5.18.06
5.18.06
5.18.06
Total

Pax3+
12
74
54
46
32
218
6
61
69
16
34
186
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Table 1. FGF Inhibitor SU5402 Cell Counts (continued)
Embryo
3

Total

Date
5.18.06
5.18.06
5.18.06
5.18.06
5.18.06
Total

Pax3+
38
25
25
27
43
158
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Table 2. FGF Inhibitor SU5402 Statistical Analysis
t-Test for Two Sample Means From Different Populations
Ho: No Difference, i.e., Difference is Not Significant
Control

Experimental

Sample Size

3

3

Sample Mean

187.333

31.330

Sample Std Dev

30.022

18.010

Degrees of Freedom = 2
Difference of Means = 156.00
t = 7.718

p = 0.016376

α = 0.050

95% Confidence Interval: 69.03 to 242.97

t* = 4.3027
Reject Ho
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Conclusion
Development of the ophthalmic trigeminal placode, like similar neurogenic
placodes, requires multiple steps. Deciphering the molecular signals and tissue
interactions involved in these processes is very complex. Studies in the otic placode have
been ongoing for two decades revealing the involvement of the hindbrain, mesoderm, and
ectoderm. These tissues are shown to be influenced by many different FGF inducing
signals as well as signaling from the Wnt pathway. Although much is known about otic
placode induction, there are still many unanswered questions and conflicting data in the
literature.
Compared to the otic placode, understanding of opV placode development is still
in its infancy. Prior to this study only the tissue interactions involved in opV placode
induction were known, without any molecular data. This study presents the first data of
its kind, revealing a role for canonical Wnt signaling in opV placode development. We
have shown that canonical Wnt signaling is necessary but not sufficient for opV placode
cell fate determination. It is possible that Wnt is acting in two ways, both early in the
initial induction of Pax3 expression and in the continued maintenance of Pax3 and
development of the placode. Because Wnt is required for placode development but can
not alone induce Pax3 expression, we have also begun to investigate possible co-factors.
Early data on FGF signaling, using a general FGF receptor inhibitor, suggests that
FGF signaling may also be required for opV induction. Two hypotheses have emerged
from this data: 1) Wnt and another secreted factor (possibly FGF) signal synergistically
to activate initial Pax3 expression thereby inducing the opV placode with continued Wnt
signaling needed to maintain Pax3 protein expression and placodal differentiation. 2) A

105

different signal, such as FGF, induces initial Pax3 expression with Wnt signaling required
to maintain Pax3 expression and promote continued development of the opV placode
(Fig. 3).
Whether Wnt is acting together with other signaling factors or in a sequential
manner is still to be determined. Nevertheless, identifying the first molecular signaling
pathway known to be involved in opV placode development is an important initial step
and will promote further research on the molecular processes involved in neurogenesis.
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Model 1.
Wnt

FGF?

Wnt

Pax3

Pax3

Competent Ectoderm

Induction
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Model 2.
Wnt

FGF?

Pax3

Pax3

Competent Ectoderm
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Figure 3. Possible Roles of Wnt Signaling
Models depicting possible roles for Wnt signaling in opV placode development. Model 1)
Wnt and another secreted factor (possibly FGF) signal synergistically to activate initial
Pax3 expression thereby inducing the opV placode with continued Wnt signaling needed
to maintain Pax3 protein expression and placodal differentiation. Model 2) A different
signal, such as FGF, induces initial Pax3 expression with Wnt signaling required to
maintain Pax3 expression and promote continued development of the opV placode
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• Research focus on cell-cell interactions and intracellular signaling in the
developing nervous system
January 2003 – April 2006
Department of Physiology & Developmental Biology, BYU
Bruce H. Woolley, PhD & Michael R. Stark, PhD
• General Biology
• Developmental & Cell Biology

Teaching Experience

June 2001 – August 2002
Department of Physiology & Developmental Biology, BYU
Michael R. Stark, PhD., Developmental Biology
• Management of laboratory inventory; ordering, organizing, and record keeping
• Instructing fellow students in laboratory techniques and safety procedures

Laboratory Technician

Skills
Laboratory techniques
•
•
•
•
•
•
•

Embryology, electroporation, and tissue culture utilizing the chick model
Manipulation of signal transduction pathways
Mammalian cell culture and transfection
DNA manipulation, subcloning, isolation, and vector construction
Immunohistochemistry, cryosection, and fluorescence microscopy
PCR, RT-PCR, and primer design
mRNA localization and isolation, RNA Interference
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Publications & Presentations
Manuscript Submitted August 2006, Developmental Biology
“Canonical Wnt Signaling is Required for Ophthalmic Trigeminal Placode Cell
Fate Determination and Maintenance” Rhonda N. T. Lassiter, Carolynn
Dude, Stephanie T. Reynolds, Nichelle I. Winters, Clare V. H. Baker,
Michael R. Stark
Book Chapter, Methods in Molecular Biology Series: Neural Stem Cells. Edited by
Zigova, T., Sandberg, P.R., Sanchez-Ramos, J.R., Humana Press, Inc.,
“Electroporation Strategies for Genetic Manipulation and Cell Labeling”
Van Raay, TJ, Lassiter, R.T., Stark, M.R.
Society for Developmental Biology. Annual Meeting, July 2005
Poster Presentation: “Induction of the Ophthalmic Trigeminal Placode is Regulated
by Canonical Wnt Signaling”
American Society for Cell Biology, Annual Meeting, December 2003
Poster Presentation: “Wnt/Frizzled Signaling in M/H Brain Boundary Formation”

Scholarships and Awards
Ted and Della Hanks Scholarship
September 2003 – April 2004
Graduate Studies Teaching Mentor Award
September 2003 – April 2004
Physiology & Developmental Biology Scholarship
September 2002 – December 2006

Affiliations
Society for Developmental Biology
American Society for Cell Biology

Additional Academic Training
Developmental Biology and Genetics
Cell Signal Transduction
Molecular Biology
Cell Biology
Biochemistry
Molecular Physiology
Biochemical and Molecular Methodologies
Model System Techniques (Mouse and Chick)
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